Ask AI
INCA033989 in MF
Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF

Released: December 11, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: December 11, 2025